A phase I/II dose-escalation study of fractionated 225Ac-J591 for progressive metastatic castration-resistant prostate cancer (mCRPC) in patients with prior treatment with 177Lu-PSMA.

被引：0
|
作者：
Nauseef, Jones T.
Sun, Michael Philip
Thomas, Charlene
Bissassar, Mahelia
Patel, Amie
Tan, Angela
Fernandez, Escarleth
Davidson, Zachary
Chamberlain, Tessa
Earle, Kara
Wunder, Rebecca
Castellanos, Sandra Huicochea
Gregos, Peter
Osborne, Joseph
Ballman, Karla V.
Molina, Ana M.
Sternberg, Cora N.
Nanus, David M.
Bander, Neil Harrison
Tagawa, Scott T.
机构：
[1] Weill Cornell Med, Div Hematol & Med Oncol, New York, NY USA
[2] Sandra & Edward Meyer Canc Ctr, New York, NY USA
[3] Weill Cornell Med, Div Hematol & Med Oncol, New York, NY USA
[4] Weill Cornell Med, New York, NY USA
[5] Weill Cornell Med Ctr, New York, NY USA
[6] Weill Cornell Med Coll, New York, NY USA
[7] Weill Cornell Med Mol Imaging & Therapeut, Dept Radiol, New York, NY USA
[8] NYP Brooklyn Methodist Hosp, Weill Cornell Med, Brooklyn, NY USA
[9] New York Presbyterian Hosp, Weill Cornell Med, New York, NY USA
[10] Cornell Univ, Weill Med Coll, NewYork Presbyterian Hosp, New York, NY USA
[11] Weill Cornell Med, Hematol Oncol, New York, NY USA
[12] NewYork Presbyterian Hosp, Div Hematol & Med Oncol, Weill Cornell Med, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS288
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Phase I dose-escalation results of prostate-specific membrane antigen-targeted radionuclide therapy (PSMA-TRT) with alpha-radiolabeled antibody 225Ac-J591 and betaradioligand 177Lu-PSMA I&T
    Tagawa, Scott T.
    Sun, Michael Philip
    Nauseef, Jones T.
    Thomas, Charlene
    Castellanos, Sandra Huicochea
    Thomas, Joseph Earl
    Davidson, Zachary
    Stangl-Kremser, Judith
    Bissassar, Mahelia
    Palmer, Jessica
    Tan, Angela
    Patel, Amie
    Molina, Ana M.
    Sternberg, Cora N.
    Nanus, David M.
    Osborne, Joseph
    Bander, Neil Harrison
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [42] Tolerability of [177Lu]Lu-PSMA-617 by treatment exposure in patients with metastatic castration-resistant prostate cancer (mCRPC): A VISION study subgroup analysis.
    Tagawa, Scott T.
    Armstrong, Andrew J.
    Krause, Bernd J.
    Herrmann, Ken
    Rahbar, Kambiz
    De Bono, Johann S.
    Adra, Nabil
    Desilvio, Michelle
    Messmann, Richard
    Holder, Geoffrey
    Chi, Kim N.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [43] ECONOMIC ANALYSIS OF 177LU-PSMA-I&T IN AUSTRALIAN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
    Ayati, Nayyereh
    INTERNAL MEDICINE JOURNAL, 2023, 53 : 31 - 31
  • [44] LuCAB: A Phase I/II trial evaluating cabazitaxel in combination with [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer
    Kostos, Louise
    Buteau, James P.
    Kong, Grace
    Opar, Petra
    Di Lulio, Juliana
    Fahey, Michael
    Fettke, Heidi
    Furic, Luc
    Hofman, Michael S.
    Azad, Arun
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2023, 19 : 77 - 77
  • [45] LuCAB: A PHASE I/II TRIAL EVALUATING CABAZITAXEL IN COMBINATION WITH (177Lu)Lu-PSMA-617 IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
    Buteau, James
    INTERNAL MEDICINE JOURNAL, 2023, 53 : 71 - 71
  • [46] A phase I dose-escalation study of LAE001/prednisone plus afuresertib in patients with metastatic castration-resistant prostate cancer (mCRPC) following standard of care (SOC) treatment
    Bessudo, A.
    Wang, X.
    Strauss, J. F.
    Slater, D. E.
    Pieczonka, C.
    Guo, P.
    Liu, J.
    Yue, Y.
    Lu, C.
    ANNALS OF ONCOLOGY, 2021, 32 : S644 - S645
  • [47] VISION: An international, prospective, open-label, multicenter, randomized phase 3 study of 177Lu-PSMA-617 in the treatment of patients with progressive PSMA-positive metastatic castration-resistant prostate cancer (mCRPC).
    Sartor, A. Oliver
    Morris, Michael J.
    Krause, Bernd J.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [48] A phase Ib study of a single priming dose of 177Lu-PSMA617 coupled with pembrolizumab in metastatic castration resistant prostate cancer (mCRPC)
    Aggarwal, R.
    Trihy, L.
    Hernandez Romero, E.
    Sam, S. Luch
    Rastogi, M.
    De Kouchkovsky, I.
    Small, E. J.
    Feng, F.
    Kwon, D.
    Friedlander, T.
    Borno, H. T.
    Bose, R.
    Chou, J.
    Koshkin, V. S.
    Desai, A.
    Feng, S.
    Angelidakis, A.
    Johnson, M. S.
    Fong, L.
    Hope, T.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1173 - S1173
  • [49] VISION: An international, prospective, open-label, multicenter, randomized phase III study of 177Lu-PSMA-617 in the treatment of patients with progressive PSMA-positive metastatic castration-resistant prostate cancer (mCRPC)
    Sartor, A. Oliver
    Morris, Michael J.
    Messman, Richard
    Krause, Bernd J.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [50] PSA flare in patients with metastatic castration-resistant prostate cancer undergoing 177Lu-PSMA treatment.
    Li, Haoran
    Wulff-Burchfield, Elizabeth Marie
    Abbasi, Saqib
    Narang, Arshit
    Dal, Emre
    Donald, Joseph
    Yap, Wendell Y.
    Shen, Xinglei
    Chen, Ronald C.
    Parikh, Rahul Atul
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 157 - 157
12345